Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs Cytokinetics Inc (CYTK) Price & Performance

ARK Autonomous Technology & Robotics ETFTrade
Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

ARK Autonomous Technology & Robotics ETF vs Cytokinetics Inc — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $129.39, while Cytokinetics Inc trades at $75.99 (market cap $10.63B). Which is the better fit depends on your goals.

ARKQCYTK
Sector
Sector/ThematicTechnology
52-Week High
$143.82$87.26
52-Week Low
$95.28$34.31
Market Cap
$10.63B
Enterprise Value
$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Autonomous Technology & Robotics ETF

ARKQ trades at $129.39, up 1.17% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on autonomous technology and robotics, with recent news highlighting Cathie Wood's continued bets on disruptive tech like SpaceX and Joby Aviation. Its portfolio has shifted toward quality and momentum names, blending defense stocks for resilience.

Outlook remains positive for long-term growth in AI and robotics, but high RSI levels suggest near-term overbought risk. Key risks include tech sector volatility and reliance on speculative holdings. Analysts view it as a hold with accumulation opportunities during pullbacks.

Cytokinetics Inc

CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.

The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.

Returns comparison

Trailing returns across standard periods

About ARK Autonomous Technology & Robotics ETF

ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.

Read more on ARKQ

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK